Story perspectives

Allogene CAR-T Therapy Shows 58% MRD Negativity in Trials

4/13/2026

Summary

Story summary

Allogene Therapeutics announced Phase 2 interim results for its off-the-shelf CAR-T therapy cema-cel in B-cell lymphoma, with 58% achieving minimal residual disease (MRD) negativity vs. 16% in controls.
The data show a significant reduction in circulating lymphoma DNA.
Allogene aims to broaden access by completing enrollment by 2027.
The findings could revive interest in allogeneic CAR-T therapies amid competition from autologous options, with event-free survival data expected mid-2027 and mid-2028.

1 of 1

Story summary

Allogene Therapeutics announced Phase 2 interim results for its off-the-shelf CAR-T therapy cema-cel in B-cell lymphoma, with 58% achieving minimal residual disease (MRD) negativity vs. 16% in controls.
The data show a significant reduction in circulating lymphoma DNA.
Allogene aims to broaden access by completing enrollment by 2027.
The findings could revive interest in allogeneic CAR-T therapies amid competition from autologous options, with event-free survival data expected mid-2027 and mid-2028.